## **Emilie Thivat**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/877101/publications.pdf

Version: 2024-02-01

41 papers

1,104 citations

393982 19 h-index 395343 33 g-index

46 all docs

46 docs citations

46 times ranked 2075 citing authors

#	Article	IF	CITATIONS
1	Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol. BMC Cancer, 2022, 22, 417.	1.1	5
2	Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in firstâ€line treatment of metastatic castrationâ€resistant prostate cancer. Cancer Medicine, 2021, 10, 2332-2340.	1.3	24
3	Adapted Physical Activity for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Trastuzumab Against HER2 (APACAN2): A Protocol for a Feasibility Study. Frontiers in Oncology, 2021, 11, 744609.	1.3	2
4	A decrease in brown adipose tissue activity is associated with weight gain during chemotherapy in early breast cancer patients. BMC Cancer, 2020, 20, 96.	1.1	15
5	Treatment-Induced Cardiotoxicity in Breast Cancer: A Review of the Interest of Practicing a Physical Activity. Oncology, 2019, 96, 223-234.	0.9	27
6	Impact of Chemotherapy-induced Menopause in Women of Childbearing Age With Non-metastatic Breast Cancer – Preliminary Results From the MENOCOR Study. Clinical Breast Cancer, 2019, 19, e74-e84.	1.1	14
7	Characterisation of gut, lung, and upper airways microbiota in patients with non-small cell lung carcinoma. Medicine (United States), 2018, 97, e13676.	0.4	28
8	Prospective Study on Body Composition, Energy Balance and Biological Factors Changes in Post-menopausal Women with Breast Cancer Receiving Adjuvant Chemotherapy Including Taxanes. Nutrition and Cancer, 2018, 70, 997-1006.	0.9	6
9	Weight Evolution During Endocrine Therapy for Breast Cancer in Postmenopausal Patients: Effect of Initial Fat Mass Percentage and Previous Adjuvant Treatments. Clinical Breast Cancer, 2018, 18, e1093-e1102.	1.1	4
10	Quality of life after mastectomy with or without immediate breast reconstruction. British Journal of Surgery, 2017, 104, 1197-1206.	0.1	105
11	Effect of an intensive 3-week preoperative home rehabilitation programme in patients with chronic obstructive pulmonary disease eligible for lung cancer surgery: a multicentre randomised controlled trial. BMJ Open, 2017, 7, e017307.	0.8	9
12	Therapeutic drug monitoring and tyrosine kinase inhibitors. Oncology Letters, 2016, 12, 1223-1232.	0.8	64
13	The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study. Oncology, 2016, 90, 69-78.	0.9	109
14	Neurotoxicity as a Prognostic Factor in Patients with Metastatic Breast Cancer Treated with Ixabepilone as a First-Line Therapy. Oncology, 2015, 88, 180-188.	0.9	4
15	Brown Adipose Tissue Activity in Relation to Weight Gain During Chemotherapy in Breast Cancer Patients: A Pilot Study. Nutrition and Cancer, 2014, 66, 1092-1096.	0.9	8
16	Hibernoma: A Clinical Model for Exploring the Role of Brown Adipose Tissue in the Regulation of Body Weight?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1-6.	1.8	28
17	Temozolomide and unusual indications: Review of literature. Cancer Treatment Reviews, 2013, 39, 125-135.	3.4	71
18	Adherence with Oral Oncologic Treatment in Cancer Patients: Interest of an Adherence Score of All Dosing Errors. Oncology, 2013, 84, 67-74.	0.9	18

#	Article	IF	CITATIONS
19	Immune status is more affected by age than by carotenoid depletion–repletion in healthy human subjects. British Journal of Nutrition, 2012, 108, 2054-2065.	1.2	16
20	Importance of metabolic changes induced by chemotherapy on prognosis of earlyâ€stage breast cancer patients: a review of potential mechanisms. Obesity Reviews, 2012, 13, 368-380.	3.1	48
21	Abstract 2694: The impact of curcumin plus docetaxel on neuroendocrine features, or not, in castration-resistant prostate cancer: A prospective study. , $2012$ , , .		0
22	Prognostic Value of Initial Tumor Parameters After Metastatic Relapse. Cancer Investigation, 2011, 29, 635-643.	0.6	14
23	Late lines of treatment benefit survival in metastatic breast cancer in current practice?. Breast, 2011, 20, 574-578.	0.9	20
24	Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse. BMC Cancer, 2010, 10, 648.	1.1	97
25	Neutrophils are immune cells preferentially targeted by retinoic acid in elderly subjects. Immunity and Ageing, 2010, 7, 10.	1.8	17
26	Dietary Methionine Restriction with FOLFOX Regimen as First Line Therapy of Metastatic Colorectal Cancer: A Feasibility Study. Oncology, 2010, 78, 205-209.	0.9	46
27	Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials. International Journal of General Medicine, 2009, 2, 129.	0.8	5
28	Loss of Bcl-2 expression in colon cancer: A prognostic factor for recurrence in stage II colon cancer. Surgical Oncology, 2009, 18, 357-365.	0.8	43
29	Metastatic Breast Cancer: Overall Survival Related to Successive Chemotherapies. What Do We Gain After the Third Line?. Cancer Investigation, 2009, 27, 81-85.	0.6	20
30	Does Regional Lymph Node Irradiation Improve the Outcome of NO and pNO Breast Cancer?. Cancer Investigation, 2009, 28, 195-200.	0.6	3
31	Combined Methionine Deprivation and Chloroethylnitrosourea Have Time-Dependent Therapeutic Synergy on Melanoma Tumors That NMR Spectroscopy-Based Metabolomics Explains by Methionine and Phospholipid Metabolism Reprogramming. Nutrition and Cancer, 2009, 61, 518-529.	0.9	9
32	Measurement of Residual Disease After Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 2008, 26, 3094-3094.	0.8	12
33	Changes and Predictive and Prognostic Value of the Mitotic Index, Ki-67, Cyclin D1, and Cyclo-oxygenase-2 in 710 Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Oncologist, 2008, 13, 1235-1245.	1.9	56
34	A New Prognostic Classification After Primary Chemotherapy for Breast Cancer: Residual Disease in Breast and Nodes (RDBN). Cancer Journal (Sudbury, Mass), 2008, 14, 128-132.	1.0	35
35	Optimal Methionine-Free Diet Duration for Nitrourea Treatment: A Phase I Clinical Trial. Nutrition and Cancer, 2007, 60, 23-30.	0.9	44
36	Temozolomide Treatment of an Adult with a Relapsing Medulloblastoma. Cancer Investigation, 2007, 25, 470-475.	0.6	21

## EMILIE THIVAT

#	Article	IF	CITATION
37	A methionine-free diet associated with nitrosourea treatment down-regulates methylguanine-DNA methyl transferase activity in patients with metastatic cancer. Anticancer Research, 2007, 27, 2779-83.	0.5	23
38	Cystemustine in recurrent high grade glioma. Journal of Neuro-Oncology, 2006, 79, 33-37.	1.4	8
39	Second-line chemotherapy of disseminated malignant melanoma with cystemustine at 60 mg/m2: a phase II trial. Anti-Cancer Drugs, 2005, 16, 1003-1007.	0.7	3
40	Long-term disease-free survival in advanced melanomas treated with nitrosoureas: mechanisms and new perspectives. BMC Cancer, 2005, 5, 147.	1.1	5
41	New Approches in Advanced Melanoma Treated by Nitrosourea. Journal of Immunotherapy, 2004, 27, S52-S53.	1.2	O